June 15, 2021

A new ASCO guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations update the 2020 guideline from ASCO, the American Society for Radiation Oncology (ASTRO), and the Society of Surgical Oncology (SSO) published on the management of hereditary breast cancer.

June 3, 2021

The addition of the immunotherapy agent toripalimab to standard first-line chemotherapy significantly delayed disease progression for patients with recurrent or metastatic nasopharyngeal carcinoma (NPC), according to new research. The phase III international study, to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, may represent a paradigm shift in the care of these patients, for whom there are currently few treatment options

June 3, 2021

Compared to standard of care chemotherapy, both a dual immunotherapy regimen and a single immunotherapy agent added to chemotherapy extends overall survival (OS) for patients with advanced esophageal squamous cell carcinoma (ESCC), particularly those positive for the immune checkpoint protein PD-L1, according to data from a phase III trial to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 3, 2021

Immunotherapy after surgery significantly improved disease-free survival (DFS) for patients with the most common type of kidney cancer, clear-cell renal carcinoma (RCC). A phase III international study, to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, found that pembrolizumab (Keytruda) could offer an effective treatment for patients currently with few other options. KEYNOTE-564 is the first phase III study with a checkpoint inhibitor in the adjuvant setting to improve DFS for patients with high risk fully resected RCC.

June 3, 2021

The addition of 1 year of the PARP inhibitor olaparib after completion of standard neoadjuvant or adjuvant chemotherapy, surgery and any radiation therapy needed, significantly improved invasive disease-free (IDFS) and distant disease-free survival (DDFS) in patients with BRCA1/2 germline mutations and high-risk early-stage breast cancer that is negative for human epidermal growth factor receptor 2-(HER2), according to new research to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

June 3, 2021

Additional chemotherapy given after standard chemoradiation treatment does not improve survival for women with locally advanced cervical cancer, and is associated with additional side effects, according to results of a phase III international trial. 

June 3, 2021

The investigational therapy 177Lu-PSMA-617 significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) when added to standard of care treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) compared with standard of care alone, according to new research. 

May 27, 2021

ALEXANDRIA, Va. - Conquer Cancer, the ASCO Foundation, is pleased to announce the recipients of its awards supporting researchers with projects spanning across many areas in cancer care, including immunotherapy, precision medicine, breast cancer, and palliative care. The awards will be given in conjunction with the 2021 ASCO Annual Meeting. 

May 26, 2021

Twenty-seven studies exploring a wide range of topics across many cancer disease sites will be presented at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place online June 4-8.

May 25, 2021

The Association for Clinical Oncology (ASCO) congratulates Chiquita Brooks-LaSure on her confirmation as Administrator of the Centers for Medicare & Medicaid Services (CMS). Administrator Brooks-LaSure is now in a key position to lead CMS during the agency’s continued response to the COVID-19 pandemic and the evolving implementation of the Affordable Care Act (ACA) under the new Administration. 

May 19, 2021

Younger African American men undergoing frequent prostate cancer screening appear to have both a lower risk of metastasis at the time of prostate cancer diagnosis and of fatal disease, according to data from an observational study to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.

May 19, 2021

Treatment with the immunotherapy atezolizumab (Tecentriq) extended disease-free survival (DFS) in patients with resected, early-stage non-small cell lung cancer (NSCLC), particularly those positive for the immune checkpoint protein PD-L1, according to new research to be presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting. The findings open the door to delaying recurrence even longer for patients with early-stage disease.

May 19, 2021

Survival for patients with newly diagnosed cancer is longer in states with higher Medicaid income eligibility limits.

May 19, 2021

When compared to anti-PD-1 monotherapy, two immunotherapy agents blocking different checkpoints extended time to disease progression for patients with previously untreated, unresectable, or metastatic melanoma, new research found.

May 19, 2021

In a review of the incidence and trends of the Human Papillomavirus- (HPV-) related cancers, a new study found that over the last 17 years, the incidence of cervical cancer has decreased annually by 1%, while the incidence of other HPV-related cancers continues to increase. 

Pages